Ultragenyx (RARE) EVP and Chief Legal Officer sells 9,526 shares

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc.’s EVP and Chief Legal Officer, Karah Herdman Parschauer, reported open-market sales of company common stock. She sold 6,018 shares on March 6, 2026 at $21.40 per share and 3,508 shares on March 10, 2026 at $22.67 per share, for total reported sales of 9,526 shares. Following these transactions, she directly holds 66,820 shares of common stock, which include previously reported shares underlying restricted stock units that are subject to vesting conditions.

Insider Trade Summary

Net Seller: 9,526 shares ($208,312)

Net Sell 2 txns

Insider Parschauer Karah Herdman

Role EVP and Chief Legal Officer

Sold 9,526 shs ($208K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,508	$22.67	$80K
Sale	Common Stock	6,018	$21.40	$129K

Holdings After Transaction: Common Stock — 66,820 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parschauer Karah Herdman

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S		6,018	D	$21.4	70,328	D
Common Stock	03/10/2026		S		3,508	D	$22.67	66,820(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ultragenyx (RARE) report for Karah Herdman Parschauer?

Ultragenyx reported that EVP and Chief Legal Officer Karah Herdman Parschauer sold 9,526 shares of common stock in open-market transactions. These sales occurred on March 6 and March 10, 2026, and were disclosed on a Form 4 insider trading report.

How many Ultragenyx (RARE) shares did the EVP sell and at what prices?

Karah Herdman Parschauer sold 6,018 Ultragenyx shares at $21.40 on March 6, 2026, and 3,508 shares at $22.67 on March 10, 2026. In total, she reported open-market sales of 9,526 common shares.

How many Ultragenyx (RARE) shares does the EVP hold after the reported sales?

After the reported open-market sales, Karah Herdman Parschauer directly holds 66,820 shares of Ultragenyx common stock. This figure includes previously reported shares underlying restricted stock units that are subject to vesting conditions, as noted in the filing’s footnote.

What type of insider transactions did Ultragenyx (RARE) disclose in this Form 4?

The Form 4 discloses two non-derivative transactions classified as open-market sales of common stock. Both transactions use code “S,” indicating sales in open market or private transactions, and there are no derivative exercises, gifts, or tax-withholding dispositions reported.

Do the Ultragenyx (RARE) insider transactions involve any stock options or derivatives?

The reported transactions involve only common stock and are non-derivative open-market sales. The derivative section of the filing shows no option or other derivative transactions, and the derivative position summary is empty in this particular Form 4.

What does the RSU footnote mean in the Ultragenyx (RARE) Form 4 filing?

The footnote explains that the reported direct holdings include previously disclosed shares underlying restricted stock units granted to Karah Herdman Parschauer. These RSUs are subject to vesting conditions, meaning the underlying shares become fully owned only as those conditions are satisfied over time.